Current Health Updates: Abortion Ban, Cancer Therapy, and Weight-loss Drug Launches

This summary highlights key health news, including Utah's Supreme Court decision on an abortion ban, Church & Dwight's financial forecast due to cautious consumer spending, FDA's approval of Adaptimmune's cancer therapy, Novo Nordisk's weight-loss drug launch in Australia, and the availability of Eli Lilly's weight-loss and diabetes drug doses.

Following is a summary of current health news briefs.

In a significant legal development, Utah's Supreme Court has refused to enforce a near-total abortion ban, upholding a lower court's decision while the law's constitutionality is challenged. The court emphasized the lawsuit raises serious constitutional issues.

Condom manufacturer Church & Dwight has revised its full-year sales and profit predictions to the lower end of its forecast due to consumer hesitancy in spending on its premium products. This forecast adjustment led to a 4.3% drop in the company's premarket shares.

The U.S. FDA has given the green light to Adaptimmune's unique therapy for synovial sarcoma, a rare cancer in the soft tissues, marking a crucial advancement in treatment options for young patients who've exhausted chemotherapy.

Novo Nordisk's popular weight-loss drug, Wegovy, has been launched in Australia, expanding its availability to 12 countries. The company is racing to meet high demand and outpace competitors like Eli Lilly.

The FDA has announced that all doses of Eli Lilly's weight-loss and diabetes drugs, Zepbound and Mounjaro, are now accessible, although the medications haven't been removed from its shortage list yet.

(With inputs from agencies.)